SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
abortion pills
'Temporary Relief Isn't Enough,' Advocates Warn After Supreme Court Blocks Abortion Pill Restrictions
"We are relieved that access to mifepristone remains protected for now, but this should never have been on the table in the first place," said one campaigner.
May 14, 2026
While welcoming that the US Supreme Court on Thursday blocked restrictions on dispensing mifepristone—a medication commonly used in abortion and miscarriage care—as a legal battle over it moves forward, rights advocates also continued to sound the alarm about attacks on reproductive freedom and argue that "temporary relief isn't enough."
At issue is the 2023 Food and Drug Administration (FDA) decision to permanently lift mifepristone's in-person dispensing requirement, which has enabled doctors to serve patients nationwide via telehealth and the mail, as forced pregnancy advocates have intensified the fight for state laws cutting off access to abortion care since the Supreme Court reversed Roe v. Wade in 2022.
Louisiana sued over the FDA's move, and early this month, the notoriously right-wing US Court of Appeals for the 5th Circuit halted the agency's rule easing restrictions. Drugmakers Danco Laboratories and GenBioPro appealed, and Justice Samuel Alito, a member of the high court's right-wing supermajority, issued a one-week stay, which he then extended to Thursday evening.
With that deadline looming, the court ultimately blocked the 5th Circuit's ruling. Alito and Justice Clarence Thomas, another right-winger, dissented.
"While it is good news that, for now, patients can continue to get this safe medication by mail and at pharmacies as they have for more than five years, we all know abortion opponents are continuing their unpopular and baseless attacks," Julia Kaye, senior staff attorney for the ACLU's Reproductive Freedom Project, said in a statement.
"And let's be clear about the Trump administration's role here: When nationwide access to a critical abortion and miscarriage medication was on the line, the Trump administration refused to defend the FDA's action and threw patients under the bus," Kaye noted. "The American people have made clear time and again that they oppose political efforts to interfere with their ability to make their own healthcare decisions—and the ACLU will keep fighting with them every step of the way."
Advocates stressed that the fight is far from over. Monica Simpson, executive director of SisterSong: Women of Color Reproductive Justice Collective, said that her organization "is relieved that the Supreme Court granted the emergency appeal to keep mifepristone accessible through telehealth and mail nationwide."
"This decision ensures that people, especially Black, brown, queer, trans, immigrant, poor, and people living in rural communities who already face barriers to healthcare, can continue accessing essential reproductive care," she noted. "While today's decision prevents immediate harm, people's lives shouldn't hang in the balance between back-and-forth litigation."
"Attacks on mifepristone have never been about safety or medicine," Simpson added. "They are about power and control—about who gets to make decisions about their body, their family, and their future."
All* Above All president Nourbese Flint also welcomed the decision while arguing that "the fact that patients and providers were forced to endure the confusion and disruption of care because of yet another court ruling on whether basic healthcare would remain available is unacceptable."
"This legal whiplash is exhausting, dangerous, and completely disconnected from science," Flint continued. "We know that mifepristone is safe and effective, and has been for over 25 years. People should not have to navigate a week-to-week roller coaster just to find out if they can still access basic healthcare and medication they need."
Serra Sippel, executive director of the Brigid Alliance, which helps people forced to travel for abortion care, similarly said that "we are relieved that access to mifepristone remains protected for now, but this should never have been on the table in the first place. Patients and providers should not be forced to wait on court rulings to know whether people can access critical healthcare."
"The back-and-forth of this case does have a cost. Confusion and uncertainty can delay care, and every day makes a difference. When people are pushed later into pregnancy, care becomes harder to access, more expensive, and many more miles further from home," Sippel explained. "We're seeing this firsthand. Last year, the Brigid Alliance helped 1,879 people travel for abortion care—a 35% increase from the year before—and those numbers will continue to rise as state abortion restrictions force more people to cross state lines for care."
Keep ReadingShow Less
Supreme Court Temporarily Extends Abortion Pill Access, But 'Care Is Still Under Attack Every Day'
"Mifepristone is safe and effective, and women should be able to get abortion medication through the mail or telehealth if they need," said Sen. Patty Murray.
May 11, 2026
Defenders of reproductive rights, including key Democrats in Congress, reiterated the safety of mifepristone on Monday after the US Supreme Court temporarily extended access to the medication—commonly used in abortion and miscarriage care—by mail while the justices review a ruling from a notoriously right-wing appellate court.
The US Court of Appeals for the 5th Circuit blocked a federal rule allowing mifepristone to be dispensed by mail at the beginning of the month. Drugmakers quickly appealed to the high court, where Justice Samuel Alito, who is part of the right-wing supermajority, issued a one-week stay to give himself and colleagues time to review the case.
As Alito's initial Monday evening deadline approached, he extended the stay until 5:00 pm ET on Thursday. The move means that "for now, mifepristone is still available via telehealth, mail order, and pharmacy while the case proceeds," noted the Democratic Women's Caucus in the US House of Representatives.
However, pro-choice advocates and policymakers are still sounding the alarm and arguing that, as the caucus put it in a social media post, "reproductive freedom should not depend on emergency rulings or political attacks."
Senate Minority Leader Chuck Schumer (D-NY) said in a statement that "mifepristone has been safe, effective, and trusted for decades. Today's order keeps access in place for now, but it's not cause for celebration—it's a reminder that basic reproductive care is still under attack every day. Anti-abortion extremists are trying to use the courts to roll back access to medication abortion nationwide, and Senate Dems will keep fighting to protect women's freedom to make their own healthcare decisions."
Sen. Patty Murray (D-Wash.) similarly wrote on social media: "Another extension, but this shouldn't be complicated. Mifepristone is safe and effective, and women should be able to get abortion medication through the mail or telehealth if they need. Extremist judges shouldn't get to decide how women get healthcare."
This case traces back to early 2023, when the Biden administration's Food and Drug Administration permanently lifted mifepristone's in-person dispensing requirement, just months after the Supreme Court's right-wing supermajority overturned Roe v. Wade. Louisiana, which has among the most restrictive abortion policies in the country, sued over the FDA's policy change.
Medication abortions account for the majority of abortions provided in the United States, and those patients generally take both mifepristone and another drug, misoprostol. Demand for abortion pills by mail increased after Roe's reversal, as advocates of forced pregnancy policies in Republican-controlled states ramped up attacks on reproductive freedom.
"With the Supreme Court punting a decision on access to mifepristone—a safe, effective medication used in abortion care—until later this week, patients and providers are left facing continued uncertainty," said Rachel Fey, interim co-CEO of Power to Decide. "Wondering day by day whether you'll have access to an essential medication is not practical, and the confusion only deepens the barriers people already face when seeking abortion care."
"Access to mifepristone should be based on scientific evidence, not ideology," Fey declared. "We urge the Supreme Court to follow that science and maintain current telehealth access to mifepristone—not just for a few days at a time, but permanently."
Alito's extensions in recent days are not necessarily signals of where the conservative will ultimately come down. The Associated Press pointed out Monday that "the current dispute is similar to one that reached the court three years ago," when the justices blocked another 5th Circuit ruling "over the dissenting votes of Alito and Justice Clarence Thomas," and then unanimously dismissed that case due to lack of standing, or a legal right to sue.
The battle comes as the Trump administration's FDA is conducting a review of mifepristone that Julia Kaye, senior staff attorney for the ACLU’s Reproductive Freedom Project, has said seems "designed to manufacture an excuse for further restricting medication abortion across the country."
The New York Times noted Monday that US Department of Justice "lawyers have not said in court proceedings or publicly whether they back regulations that allow people to be prescribed the pills through telehealth appointments. Instead, they have asked the lower courts to pause the litigation to give the FDA time to complete a review of the safety of mifepristone, which was first approved in 2000."
Keep ReadingShow Less
Access to Abortion Pill by Mail Restored—For Now—During US Supreme Court Review
"While this is a positive short-term development, no one can rest easy when our ability to get this safe, effective medication for abortion and miscarriage care still hangs in the balance," stressed an ACLU attorney.
May 04, 2026
The US Supreme Court on Monday temporarily restored access to mifepristone, a medication commonly used for abortion and early miscarriage care, through the mail while the justices review a decision requiring it to be dispensed in person by a medical provider.
Justice Samuel Alito, who is part of the high court's right-wing supermajority, oversees the US Court of Appeals for the 5th Circuit. He issued a one-week stay for the appellate court's Friday dispensing decision, which critics had condemned as "sweeping and dangerous."
"This is not particularly surprising from Alito. He's the circuit justice here, acting—in essence—until the full court can act," explained Law Dork's Chris Geidner. He noted that both Alito and Justice Clarence Thomas, another right-winger, "have issued administrative stays in the past until the full court can rule in similar circumstances, regardless of their ultimate votes on the matters."
The drug companies Danco Laboratories, which makes the brand-name version of mifepristone, Mifeprex, and GenBioPro, which makes the generic pill, asked the country's top court to intervene following Friday's ruling, which threatened patients nationwide.
"Even this Supreme Court can see that this 5th Circuit decision is reckless," declared Alexis McGill Johnson, president and CEO of Planned Parenthood Action Fund, on Monday. "While mifepristone access returns to where it was on Friday morning, the whiplash and chaos that patients and providers are navigating have already had real consequences for real people's lives and futures."
Brittany Fonteno, president and CEO of the National Abortion Federation, similarly highlighted how "this back-and-forth has created confusion and chaos," but welcomed that the high court's "decision provides critical, if temporary, relief for patients and providers and ensures that people can continue to access this essential medication through telehealth while the court considers the case."
"The lower court's ruling disregards the well-established safety and efficacy of the use of mifepristone via telehealth, and any future restriction will create medically unnecessary barriers to care for patients across the country," Fonteno added. "Mifepristone has been safely used for more than 25 years, and is essential to abortion care and miscarriage management in the United States. For many patients, especially those in rural areas or facing financial and logistical barriers, access to telehealth is a critical component of holistic reproductive healthcare."
Since the Supreme Court reversed Roe v. Wade in June 2022, the anti-choice movement and right-wing politicians have ramped up attacks on reproductive freedom at the state level. Meanwhile, the Biden administration's Food and Drug Administration (FDA) permanently lifted mifepristone's in-person dispensing requirement in early 2023, allowing doctors in pro-choice states to serve patients across the country via telehealth and the mail, regardless of local laws.
Louisiana responded to the eased restrictions on mifepristone—which is generally taken with another drug, misoprostol, for abortions—by suing, which led to the battle that has now reached the Supreme Court. Prior to Friday's decision by the infamously far-right 5th Circuit, a district judge in the state paused the case due to what the ACLU on Monday called "a sham FDA review announced by the Trump administration," which is ongoing.
"While this is a positive short-term development, no one can rest easy when our ability to get this safe, effective medication for abortion and miscarriage care still hangs in the balance," Julia Kaye, senior staff attorney for the ACLU's Reproductive Freedom Project, stressed Monday. "The Supreme Court needs to put an end to this baseless attack on our reproductive freedom, once and for all."
This article has been updated with comment from the National Abortion Federation.
Keep ReadingShow Less
Most Popular